Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (1401)	10/27/2006 5:47:04 PM
From: JMarcus	Read Replies (1) \| Respond to of 1494

Biomaven may agree with you: Message 22943628 But not TexasDude: Message 22943699 Any thoughts on the NUVO product? Marc

To: John McCarthy who wrote (1401)	10/28/2006 2:28:43 AM
From: dr.praveen	Read Replies (1) \| Respond to of 1494

Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase Phase IIB/III Stroke Study DIAS-2 Friday October 27, 11:08 pm ET NEW YORK, Oct. 27 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX - News) and its development partner for desmoteplase, PAION AG (Aachen, Germany), today announced that the independent Data Monitoring Committee (DMC) for the DIAS-2 Phase IIB/III study met and informed the Steering Committee and the Companies that it has reviewed the cumulative data from the study provided by the Companies and recommended the resumption of patient enrollment into DIAS-2 with no modification of the protocol. At this meeting, the DMC reviewed data from 170 randomized subjects. The DIAS-2 study is evaluating PAION's drug candidate desmoteplase in patients with acute ischemic stroke. The Companies continue to expect that enrolment will be completed by the end of 2006 and that study results will be available by the middle of 2007.